Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 806.08M P/E - EPS this Y -6.90% Ern Qtrly Grth -
Income -116.8M Forward P/E -7.03 EPS next Y 10.70% 50D Avg Chg 12.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg 9.00%
Dividend N/A Price/Book 3.65 EPS next 5Y - 52W High Chg -28.00%
Recommedations 2.20 Quick Ratio 7.28 Shares Outstanding 34.80M 52W Low Chg 51.00%
Insider Own 1.81% ROA -36.14% Shares Float 27.52M Beta 0.47
Inst Own 102.66% ROE -59.56% Shares Shorted/Prior 3.30M/3.51M Price 23.47
Gross Margin - Profit Margin - Avg. Volume 289,940 Target Price 23.13
Oper. Margin - Earnings Date May 9 Volume 136,748 Change -0.13%
About RAPT Therapeutics, Inc.

RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. RAPT Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Company

RAPT Therapeutics, Inc. News
03/22/24 What Makes RAPT Therapeutics (RAPT) an Investment Choice?
03/07/24 Should You Buy RAPT Therapeutics (RAPT) Ahead of Earnings?
03/07/24 RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
03/05/24 RAPT Therapeutics Announces Multiple Late-Breaking Presentations at the Upcoming American Association for Cancer Research (AACR) Annual Meeting
02/21/24 Insider Buyers Lose Additional US$63k As RAPT Therapeutics Dips To US$236m
02/20/24 Rapt Therapeutics Crashes 74% After Unexpected Liver Failure Sidelines Two Tests
02/20/24 RAPT Therapeutics Stock Is Down 63%. FDA Halts 2 Studies After Liver Failure.
02/20/24 UPDATE 1-FDA puts on hold two Rapt Therapeutics mid-stage drug trials
02/20/24 RAPT Therapeutics Announces Clinical Hold on Studies Evaluating Zelnecirnon
02/20/24 FDA puts hold on Rapt trials of drug for eczema, asthma
02/13/24 RAPT Therapeutics Bolsters Leadership Team with the Appointment of Nipun Davar, Ph.D., as Senior Vice President of Technical Operations
01/31/24 RAPT Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
01/02/24 RAPT Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
11/27/23 RAPT Therapeutics Announces Publication of Phase 1a/1b Clinical Trial of Zelnecirnon (RPT193) to Treat Atopic Dermatitis in Allergy
11/14/23 RAPT Therapeutics Inc Reports Increased R&D Expenses Amid Progress in Clinical Trials
11/13/23 RAPT Therapeutics Reports Third Quarter 2023 Financial Results
11/03/23 RAPT Therapeutics Announces Positive Data, Including Objective Response Rates and Progression-Free Survival, from its Phase 2 Trial of FLX475 in Combination with a Checkpoint Inhibitor in Patients with Advanced NSCLC
11/01/23 RAPT Therapeutics to Participate in Several Upcoming Investor Conferences in November
10/18/23 RAPT Therapeutics Announces Two FLX475 Presentations at the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting
09/27/23 7 ‘Strong Buy’ Biotech Stocks to Rejuvenate Your Portfolio
RAPT Chatroom

User Image YoungCheesy Posted - 13 hours ago

$RAPT ok let get down to business here. Cant wait to hear more about tivu presentation this April

User Image YoungCheesy Posted - 13 hours ago

@buythehornz127 come look at $RAPT :)

User Image HamBoneXoXo Posted - 17 hours ago

$RAPT Highly impressive that 103% of outstanding is owned by institutions. The 3 percent is likely due to loaned short shares. This high percentage explains why they are not many here at ST crying as it dropped from 26 to 6. They are just cool investors who wait it out.

User Image n4turallybetter Posted - 21 hours ago

$RAPT added another 150 shares on a strong bullish signal here today, let’s make money

User Image ace6th Posted - 1 day ago

$RAPT JPM looking to get in before run?

User Image StardustTrader Posted - 1 day ago

$RAPT pithy volume is easy to take down. Don't get too excited yet.

User Image HamBoneXoXo Posted - 1 day ago

$RAPT This poor ticker is the hardest working ticker I have seen. Dropped over $20 in seconds but been trying to get back up a penny at a time. Commending efforts.. at a dime up a day, we will reach $26 in 6 month.

User Image n4turallybetter Posted - 1 day ago

$RAPT just added another $500 I love this stock

User Image Greenwood31 Posted - 1 day ago

$RAPT 9+++

User Image yilongma2024 Posted - 1 day ago

$RAPT FDA hold lift coming soon?

User Image FindTruthPeace Posted - 1 day ago

$RAPT Money flow, RSI and MACD looking bullish here today. Nice

User Image FindTruthPeace Posted - 1 day ago

$RAPT still under radar for many. They will arrive late to the party and chase. I prefer to be a month or three months early. Much more money arriving early. Sometimes been way to early, like a year and could've been to a few other parties in that time, but even then...a year early has got me many doubles and triples over the years. Worst is coming late to a party and getting stuck there trying to clean up the mess. Be early. Be patient. My cost basis here in RAPT is about $7.80 now. Been accumulating since the dip. $ALT been there since Dec and added probably my last chunk today at $6.70. Cost basis now under $8. In Chill mode now waiting for the parties in both to get underway.

User Image Greenwood31 Posted - 1 day ago

$RAPT 9$ coming

User Image FindTruthPeace Posted - 1 day ago

$RAPT Didn't think my RAPT would trade above my $ALT, but heck, they both are easy doubles from here over the next few months past $15+. Which one crosses that $15 first, no clue. Either can have a rocket ship north news drop at any time. ALT is in my opinion is tad more de-risked after their ER today (both are significant derisked investments), but has heavier shorts/off-exchange volume caping share price short term, maybe...Both great park and hold doubles or more in the making. DYOR

User Image ace6th Posted - 1 day ago

$RAPT I can hold and add a long time, this is $25 + down the road.

User Image BayAreaBiotech Posted - 1 day ago

$RAPT There is a lot of discussion on the board related to Ashwagandha causing liver damage, which can be supported by scientific journals. However, there is not much discussion on this board around COVID-19 and liver failure. The patient in question also had COVID-19. There are several studies that highlight the correlation between liver damage and COVID-19. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9753058/#:~:text=Patients%20with%20COVID%2D19%20experience,disease%5B5%2D7%5D.

User Image Haha1978 Posted - 1 day ago

$RAPT capr had a voluntary hold on its drug on early January and it was resolved by mid February so it was roughly 40 days.

User Image Haha1978 Posted - 1 day ago

$RAPT not selling and holding. The fda letter can come any time between April and July but thats only if the company doesnt submit the response letter promptly. Time is money so they are on it imo.

User Image Haha1978 Posted - 1 day ago

$RAPT average time lines for clinical holds is just under 6 months. But per the fda guidelines the fda has to respond to the complete response letter submitted by the company within 30 days from receipt. So if the company got it submitted within 30 days we could be April 16th give or take. It sounds like they already had the information. The guy fried his liver on supplements. Screen shot of fda guidance.

User Image FindTruthPeace Posted - 1 day ago

@DonCorleone77 That means it's a BUY and they are accumulating on their lowered guidance. To funny. This will double from here by June. $RAPT

User Image YoungCheesy Posted - 1 day ago

$RAPT my next main biotech swing play. I like it here

User Image DonCorleone77 Posted - 1 day ago

$RAPT Rapt Therapeutics price target lowered to $13 from $15 at JPMorgan JPMorgan analyst Anupam Rama lowered the firm's price target on Rapt Therapeutics to $13 from $15 and keeps a Neutral rating on the shares. The analyst updated the company's model to include expenses and share count.

User Image HamBoneXoXo Posted - 1 day ago

$RAPT What is up with all these posts suddenly zeroing in on saying it would take six month? You know they are splitting atoms; just one patient determination of the cause of liver failure. My estimate is two month and the two month is up on April 16. Iovance had patients who died and it cleared fda in 60 days.

User Image RamenLives Posted - 1 day ago

$RAPT If we are lucky maybe news in about 2 months but more likely 6 months... it would be nice though for leadership to give monthly updates as to progress with the FDA.

User Image HamBoneXoXo Posted - 2 days ago

$RAPT Verbal note apparently on 16 Feb, so more than a month already.

User Image BigErvy Posted - 2 days ago

$RAPT Clinical holds average about 6 months.

User Image StardustTrader Posted - 2 days ago

$RAPT over 1 month with no news .. feel bad for those that expected immediate gratification

User Image Processing21 Posted - 3 days ago

$OCGN Sorry if you’re triggered. Just want people to make some money while they wait for longer term holds. Trains boarding rn 🤷🏽‍♂️ $MCRB $RAPT $ICU

User Image Processing21 Posted - 3 days ago

$OCGN It’s funny how genuinely trying to share a good stock pisses people off 😂🖕 $MCRB $RAPT $ICU

User Image Son_of_Shango Posted - 3 days ago

$RAPT

Analyst Ratings
JP Morgan Neutral Mar 27, 24
UBS Neutral Feb 22, 24
Barclays Overweight Feb 21, 24
Leerink Partners Market Perform Feb 21, 24
HC Wainwright & Co. Neutral Feb 21, 24
JP Morgan Neutral Feb 21, 24
Cantor Fitzgerald Neutral Feb 20, 24
Evercore ISI Group Outperform Feb 16, 24
Wolfe Research Outperform Feb 15, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Brockstedt Dirk G. CHIEF SCIENTIFIC OFF.. CHIEF SCIENTIFIC OFFICER Jan 05 Sell 22.78 898 20,456 27,820 01/08/24
HO WILLIAM Chief Medical Office.. Chief Medical Officer Oct 03 Sell 15.77 2,500 39,425 18,789 10/04/23
HO WILLIAM Chief Medical Office.. Chief Medical Officer Aug 18 Sell 18.92 2,500 47,300 21,289 08/22/23
HO WILLIAM Chief Medical Office.. Chief Medical Officer Jun 23 Option 12 920 11,040 23,329 06/27/23
HO WILLIAM Chief Medical Office.. Chief Medical Officer Apr 19 Sell 18.88 5,000 94,400 20,992 04/20/23
HO WILLIAM Chief Medical Office.. Chief Medical Officer Apr 13 Option 12 460 5,520 22,381 04/14/23
Robbins Wendye Director Director Mar 14 Buy 19.31 5,000 96,550 6,500 03/15/23
HO WILLIAM Chief Medical Office.. Chief Medical Officer Mar 07 Sell 29.62 5,000 148,100 25,532 03/13/23
HO WILLIAM Chief Medical Office.. Chief Medical Officer Jan 24 Sell 30 5,000 150,000 30,072 01/26/23
HO WILLIAM Chief Medical Office.. Chief Medical Officer Jan 19 Sell 25.56 5,000 127,800 35,072 01/20/23
Brockstedt Dirk G. Chief Scientific Off.. Chief Scientific Officer Jan 05 Sell 21.966 742 16,299 19,070 01/09/23
HO WILLIAM Chief Medical Office.. Chief Medical Officer Dec 29 Sell 18.03 5,000 90,150 37,650 12/30/22
HO WILLIAM Chief Medical Office.. Chief Medical Officer Nov 28 Sell 17.87 5,000 89,350 42,650 11/29/22
HO WILLIAM Chief Medical Office.. Chief Medical Officer Sep 01 Option 9.15 808 7,393 53,843 09/06/22
HO WILLIAM Chief Medical Office.. Chief Medical Officer Aug 30 Sell 28.13 2,500 70,325 53,035 08/31/22
HO WILLIAM Chief Medical Office.. Chief Medical Officer Aug 12 Option 9.15 807 7,384 55,535 08/15/22
HO WILLIAM Chief Medical Office.. Chief Medical Officer Jul 11 Option 9.15 2,422 22,161 54,728 07/13/22
HO WILLIAM Chief Medical Office.. Chief Medical Officer Jul 11 Sell 19.95 2,000 39,900 52,306 07/13/22
COLUMN GROUP II, LP 10% Owner 10% Owner May 10 Buy 10.67 1,250,000 13,337,500 41,250 05/12/22
Young Rodney KB Chief Financial Offi.. Chief Financial Officer May 10 Buy 10.53 5,000 52,650 10,084 05/12/22
Robbins Wendye Director Director May 10 Buy 10.88 7,000 76,160 4,000 05/12/22
Brockstedt Dirk G. Chief Scientific Off.. Chief Scientific Officer May 04 Sell 15.05 720 10,836 19,812 05/05/22
Brockstedt Dirk G. Chief Scientific Off.. Chief Scientific Officer Apr 11 Option 6.18 2,647 16,358 22,459 04/12/22
Brockstedt Dirk G. Chief Scientific Off.. Chief Scientific Officer Apr 11 Sell 23.05 2,647 61,013 19,812 04/12/22
HO WILLIAM Chief Medical Office.. Chief Medical Officer Apr 11 Option 12 920 11,040 54,306 04/12/22
HO WILLIAM Chief Medical Office.. Chief Medical Officer Apr 04 Option 6.3 695 4,378 56,386 04/04/22
HO WILLIAM Chief Medical Office.. Chief Medical Officer Feb 28 Sell 18.79 3,000 56,370 55,691 02/28/22
Brockstedt Dirk G. Chief Scientific Off.. Chief Scientific Officer Feb 11 Option 6.18 2,647 16,358 22,459 02/14/22
Brockstedt Dirk G. Chief Scientific Off.. Chief Scientific Officer Feb 11 Sell 22.47 2,647 59,478 19,812 02/14/22
HO WILLIAM Chief Medical Office.. Chief Medical Officer Feb 08 Option 9.15 807 7,384 58,691 02/09/22
HO WILLIAM Chief Medical Office.. Chief Medical Officer Jan 13 Sell 30.67 3,000 92,010 57,884 01/14/22
Brockstedt Dirk G. Chief Scientific Off.. Chief Scientific Officer Jan 11 Option 6.18 2,648 16,365 22,460 01/13/22
Brockstedt Dirk G. Chief Scientific Off.. Chief Scientific Officer Jan 11 Sell 32.16 2,648 85,160 19,812 01/13/22